VANCOUVER and MINNEAPOLIS - (NewMediaWire) - August 13, 2020 - Neovasc, Inc.(NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today provided a corporate update on progress towards its value creation strategies.Fred Colen, Chief Executive Officer of Neovasc, commented, "We are pleased to provide acorporate updateto...
Read MoreVancouver, Canada - (NewMediaWire) - August 12, 2020 - Neovasc Inc. (Neovasc or the Company) (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the Offering)priced at-the-market under the Nasdaq rules of an aggregate of 4,532,772 common shares at a purchase...
Read MoreVancouver - (NewMediaWire) - August 10, 2020 - Neovasc Inc. (Neovasc or the Company) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 4,532,772 common shares at a...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, August 6, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, CA, MINNEAPOLIS, US and FRANKFURT, DE, July 24, 2020 – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that the Neovasc Reducer™ (the “Reducer”) was featured in a supplement titled: “Volkskrankheiten” or “Common Diseases” in Frankfurter Allgemeine Zeitung (FAZ),...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, – July 23, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”) exercised 1,424,049 of the 2,573,959 common share purchase warrants (the “May Warrants”) issued pursuant to a Securities Purchase...
Read MoreNASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, July 9, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Committee will review the...
Read MoreCompany to Report Full Financial Results on August 6, 2020 NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, July 6, 2020 – Neovasc, Inc. (NASDAQ, TSX: NVCN), today announced preliminary revenue results for the second quarter of 2020. Revenue for the quarter ended June 30, 2020 was approximately $295,000. Revenues...
Read More